

## ASX Announcement

### Race online Q&A investor briefing invitation

**30 November 2021** – Race Oncology Limited (**Race** or the **Company**) (ASX: RAC) is pleased to invite our shareholders and interested investors to attend a special online Q&A session to discuss the Company's current Share Purchase Plan and any questions relating to the strategic update released at last week's Annual General Meeting.

Race Managing Director and CEO, Phil Lynch commented, *"We look forward to welcoming any investor interested in Race's Share Purchase Plan and strategic outlook to attend this session. During the meeting, our CSO / Executive Director, Dr Daniel Tillett; our CMO, Dr David Fuller and I will be available to answer any questions on these topics, and to also address any general questions on Race's progress and plans."*

#### Session details

Date: Wednesday 8 December

Time: From 17:30 AEDT (5.30pm Sydney time)

Register: Investors are invited to register ahead of time [via this link](#). Session info will then be emailed to your registered email address.

Outside of the Q&A session, investors seeking general information on Race's Share Purchase Plan can find a variety of resources, including on Company background, FAQs and how to complete the offer documentation at <https://spp.raceoncology.com>.

-ENDS-

#### About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines to improve their ability to target breast cancer. Race is evaluating this discovery.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene.

Learn more at [www.raceoncology.com](http://www.raceoncology.com)

**Release authorised by:**

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors  
[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

**Media contact:**

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)